Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma
Metrics: PDF 541 views | HTML 859 views | ?
Delphine Serre1, Julia Salleron2, Marie Husson3, Agnès Leroux4, Pauline Gilson4, Jean-Louis Merlin4, Lionnel Geoffrois1 and Alexandre Harlé4
1Institut de Cancérologie de Lorraine, Département d’Oncologie Médicale, Vandoeuvre-lès-Nancy Cedex 54519, France
2Institut de Cancérologie de Lorraine, Cellule Data Biostatistiques, Vandoeuvre-lès-Nancy Cedex 54519, France
3Institut de Cancérologie de Lorraine, Biopathologie, Vandoeuvre-lès-Nancy Cedex 54519, France
4Université de Lorraine, CNRS UMR 7039 CRAN, Institut de Cancérologie de Lorraine, Service de Biopathologie, Vandoeuvre-lès-Nancy Cedex 54519, France
Alexandre Harlé, email: firstname.lastname@example.org
Keywords: metastatic melanoma; BRAF; automated real-time PCR; therapeutic management
Received: May 02, 2018 Accepted: July 31, 2018 Published: August 14, 2018
Background: Determination of BRAF status is important for the therapeutic management of patients with metastatic melanoma.
Objectives: We evaluated the impact of a faster determination of BRAF mutational status on the delay between initial consultation and initiation of treatment.
Results: For the FA-PCR group a median delay of 16 days [11;18] was observed between initial consultation and the implementation of treatment, which was significantly lower than that observed for the SOP group (26 days [20;46], p = 0.035).
Conclusions: In comparison to using conventional SOP, using an FA-PCR platform for BRAF mutation analysis of patients with metastatic melanoma significantly reduced the delay in initiation of personalized therapy by 10 days.
Materials and Methods: Analysis of the BRAF mutation status of eight formalin-fixed paraffin-embedded (FFPE) tissue samples was performed using a CE-IVD fully-automated (FA) PCR-based platform. The delay between initial consultation and the implementation of treatment was compared between these samples (FA-PCR group) and a retrospective group of 29 FFPE samples analysed by standard operating procedures (SOP group) using conventional PCR.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.